This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Geron, Oculus, BioSante

BOSTON, Mass. ( TheStreet) -- Readers have been generous with their emails lately. Thank you! And keep your questions coming. I can't answer every email I receive, but I decided to open the Biotech Stock Mailbag early this week in an attempt to whittle down the backlog.

Check back again Friday for the regularly scheduled Mailbag. One more thing: I'm taking a much-needed vacation, so the Mailbag will be on a short hiatus until the first week in September.

Let's get started with an email from Robert B., who writes, "I was wondering what your reaction is (if any) to the FDA's hold on Geron's (GERN - Get Report) spinal cord therapy. I own some, and not sure how to take the news."

The first thing I did after reading Tuesday's announcement was laugh because the delays and missteps in Geron's over-hyped embryonic stem cell trial for severe spinal cord injuries are pretty much working out the way I thought they would.

Ever notice how Geron does a great job of heralding the prospect of scientific achievements and breakthroughs, yet never seems to actually deliver on its promises?

In this case, Geron promised to enroll the first paralyzed patients into its stem cell trial during the summer. That announcement was made in January. Yet August is rolling toward a hot and humid finish here in the Northeast, and the study is nowhere close to starting. Last month, the company told investors that car airbags were partly to blame for the delay. (Airbags protect drivers and passengers in accidents, making it hard to find traffic accident victims with paralysis severe enough to be eligible for the clinical trial, or so Geron CEO Tom Okarma said on his company's quarterly conference call.)
1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
GERN $4.52 5.36%
GILD $107.78 1.14%
OCLS $1.17 2.63%
PG $75.90 -0.72%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs